Andere Sprachen Cytokinetics, Incorporated Deutsche Boerse AG

Aktien

A1W1KK

US23282W6057

KK3A

Realtime-Estimate Tradegate Andere Börsenplätze 14:48:49 28.05.2024			% 5 Tage	% 1. Jan.
44.2 ^EUR	+0.45%		-20.00%	-40.54%

24.05.	CYTOKINETICS, INCORPORATED : Raymond James behält die Bewertung Kaufen bei	ZM
24.05.	CYTOKINETICS, INCORPORATED : Bewertung von Needham & Co. kaufen	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday	23.05.
Nvidia Earnings Fuel Investor Optimism, Driving Premarket Gains for US Equity Futures	23.05.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Rally on NVIDIA Earnings	23.05.
Stocks in motion: e.l.f Beauty soars along with Nvidia	23.05.
Top Premarket Decliners	23.05.
Cytokinetics Prices $500 Million Common Stock Offering	23.05.
Cytokinetics Announces Pricing of Public Offering of Common Stock	23.05.
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline	22.05.
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours	22.05.
Cytokinetics Announces Proposed Public Offering of Common Stock	22.05.
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline	22.05.
Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma plc	22.05.
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology	17.05.
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors	17.05.
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024	15.05.
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress	13.05.
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine	13.05.
Cytokinetics Q1 Net Loss Narrows, Revenue Declines	08.05.
Cytokinetics: Q1 Earnings Snapshot	08.05.
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Posts Q1 Revenue $835,000, vs. Street Est of $0.9M	08.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cytokinetics, Incorporated Deutsche Boerse AG

Aktien

A1W1KK

US23282W6057

KK3A

Andere Sprachen

Filter